Oestrogel (Estradiol)

Estradiol, the active ingredient in Oestrogel, is an estrogen presented as a gel for topical use. It treats menopausal symptoms and other estrogen‑deficiency states in women. GNH USA supplies Oestrogel as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Oestrogel as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Oestrogel is an estrogen therapy that addresses conditions related to low estrogen levels.

- Menopausal vasomotor symptoms: Reduces frequency and severity of hot flashes. - Prevention of osteoporosis: Helps maintain bone mineral density. - Hypo‑estrogenism due to ovarian failure: Restores estrogenic activity for symptom relief.

Adverse reactions to Oestrogel vary in frequency and severity.

Common Side Effects: - Skin irritation at application site: Redness or itching. - Breast tenderness: Mild discomfort or swelling. - Headache: Transient mild headache. - Nausea: Occasional mild nausea. - Mood changes: Slight irritability or mood swings.

Serious or Rare Side Effects: - Venous thromboembolism: Deep vein thrombosis or pulmonary embolism. - Stroke: Ischemic or hemorrhagic events. - Gallbladder disease: Biliary colic or cholecystitis. - Liver dysfunction: Elevated liver enzymes or hepatitis. - Hormone‑dependent tumor growth: Potential stimulation of breast or endometrial cancer.

When using Oestrogel, consider the following safety measures:

- Contraindications: Do not use in women with known estrogen‑dependent tumors. - Cardiovascular risk: Assess patients with history of thromboembolic events. - Liver function: Monitor hepatic enzymes in patients with liver disease. - Pregnancy and lactation: Avoid if pregnancy is possible or while breastfeeding. - Storage: Store below 25°C: keep in the original pack, protect from moisture.

Oestrogel can interact with several medicines, requiring monitoring or avoidance.

Major Interactions (Avoid): - Oral anticoagulants: May increase bleeding risk. - CYP3A4 inhibitors: Elevate estradiol plasma levels. - Hormonal contraceptives: May alter efficacy.

Moderate Interactions (Monitor Closely):\n- Antihypertensive drugs: Potential additive blood‑pressure effects. - Thyroid hormone replacement: May affect thyroid hormone requirements. - Anticonvulsants: May reduce estradiol concentrations.